• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.

作者信息

Sharaiha Reem Z, Shukla Alpana P, Sen Sudipta, Chan Walter C, Broome David T, Anca Diana, Abidi Wasif, Marya Neil, Muniraj Thiruvengadam, Thosani Nirav, Schulman Allison R

机构信息

Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, USA.

Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

出版信息

Gastrointest Endosc. 2025 Feb;101(2):285-294. doi: 10.1016/j.gie.2024.10.057.

DOI:10.1016/j.gie.2024.10.057
PMID:39892967
Abstract
摘要

相似文献

1
American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
Gastrointest Endosc. 2025 Feb;101(2):285-294. doi: 10.1016/j.gie.2024.10.057.
2
Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association.接受胰高血糖素样肽-1受体激动剂、葡萄糖依赖性促胰岛素多肽激动剂和钠-葡萄糖协同转运蛋白2抑制剂治疗的成人患者围手术期的择期管理：多学科共识声明：来自麻醉医师协会、英国临床糖尿病学家协会、英国肥胖与代谢外科学会、围手术期护理中心、英国住院糖尿病患者联合学会、皇家麻醉医师学院、肥胖与减重麻醉学会以及英国临床药学协会的共识声明
Anaesthesia. 2025 Apr;80(4):412-424. doi: 10.1111/anae.16541. Epub 2025 Jan 9.
3
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).改善 1 型糖尿病的肥胖治疗（OTID）：胰高血糖素样肽 1 类似物和钠-葡萄糖共转运蛋白 2 抑制剂联合治疗的随机对照试验——改善 1 型糖尿病的肥胖治疗（OTID 试验）方案。
Trials. 2024 Feb 16;25(1):129. doi: 10.1186/s13063-024-07930-3.
4
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖协同转运蛋白 2 抑制剂、二肽基肽酶-4 抑制剂和磺脲类药物治疗威胁视力的糖尿病视网膜病变的疗效比较。
Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11.
5
Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.上消化道内镜检查前应用胰高血糖素样肽-1 受体激动剂与发生吸入性肺炎或中止操作的风险：队列研究。
BMJ. 2024 Oct 22;387:e080340. doi: 10.1136/bmj-2024-080340.
6
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病的一线治疗：成本效益研究。
Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4.
7
Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂与心肺功能适应性的相互作用。
Mil Med. 2024 Nov 5;189(11-12):2369-2373. doi: 10.1093/milmed/usae311.
8
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.2 型糖尿病的患者重要结局：钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的范例。
Diab Vasc Dis Res. 2024 Jul-Aug;21(4):14791641241269743. doi: 10.1177/14791641241269743.
9
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.基于人群队列研究的 2 型糖尿病患者胰高血糖素样肽-1 受体激动剂与钠-葡萄糖共转运蛋白 2 抑制剂的心血管比较效果。
Diabetes Obes Metab. 2022 Aug;24(8):1623-1637. doi: 10.1111/dom.14741. Epub 2022 May 25.
10
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在心血管和肾脏保护方面的作用：一种超越降血糖作用的治疗方法。
Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17.

引用本文的文献

1
Peri-Procedural Safety of GLP-1 Receptor Agonists in Elective Endoscopy: A Multicenter Retrospective Cohort Study.GLP-1受体激动剂在择期内镜检查中的围手术期安全性：一项多中心回顾性队列研究
J Clin Med. 2025 Aug 30;14(17):6147. doi: 10.3390/jcm14176147.